Dr Reddy’s Laboratories and its subsidiary, Promius Pharma today announced filing of three new drug applications (NDAs) with the US Food and Drug Administration.
Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid, the company said in a filing to the BSE today.
Raghav Chari, Executive Vice President of Proprietary Products at Dr Reddy’s and President of Primus Pharma said “These products represent new, compelling options for segments of patients suffering from Psoriasis, Rosacea and Migraine”.
They are also the first of a large basket of products targeting conditions predominantly treated by dermatologist and neurologists. Upon approval, the products will be commercialised by Promius Pharma.
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…